• ABT-888 (Veliparib): Applied DNA Repair Inhibition in Cancer

  2026-04-25

  ABT-888 (Veliparib) empowers researchers to precisely inhibit DNA repair, enabling robust chemo- and radiosensitization in preclinical cancer models—especially those with microsatellite instability. This guide delivers actionable protocols, troubleshooting tactics, and context from the latest DNA damage response research, making ABT-888 from APExBIO an essential tool for translational oncology.

• Gefitinib (ZD1839): Precision EGFR Inhibition in Assembloid

  2026-04-24

  Gefitinib (ZD1839) empowers cancer researchers to dissect EGFR-driven tumor biology within physiologically relevant assembloid models. This guide translates recent breakthroughs into actionable workflows, protocol tips, and troubleshooting strategies for maximizing the translational impact of selective EGFR inhibition.

• HyperScribe T7 High Yield RNA Synthesis Kit: Workflow & Trou

  2026-04-24

  The HyperScribe™ T7 High Yield RNA Synthesis Kit empowers researchers to execute high-yield, customizable RNA synthesis workflows for advanced applications like RNA interference and vaccine development. Explore stepwise protocol enhancements, troubleshooting essentials, and data-driven insights inspired by the latest mechanistic OSCC metastasis research.

• Biotin-16-UTP: Enhancing RNA Detection and Purification Work

  2026-04-23

  Biotin-16-UTP empowers researchers to label RNA with high specificity for advanced detection, purification, and interaction assays. Discover how this biotin-labeled uridine triphosphate streamlines experimental workflows, overcomes common obstacles, and enables high-impact applications in molecular biology and cancer biomarker research.

• GABRA1 Frameshift Variants Disrupt GABAA Receptor Proteostas

  2026-04-23

  Williams et al. reveal how distinct frameshift mutations in the GABRA1 gene impair the folding, trafficking, and degradation of the GABAA receptor α1 subunit. Their mechanistic study highlights the molecular diversity in proteostasis defects underlying genetic epilepsy, offering models and methodological insight for future research on membrane protein biogenesis.

• U-73122: Potent Phospholipase C Inhibitor for Precise Pathwa

  2026-04-22

  U-73122 is a selective phospholipase C inhibitor that robustly disrupts PLC-β2-driven signaling, enabling precise modulation of calcium flux and chemotaxis in inflammation and cancer models. Peer-reviewed evidence demonstrates its efficacy in both in vitro and in vivo settings, supporting its application in dissecting PLC-dependent pathways for apoptosis and inflammation research.

• Accelerating Translational Discovery: Fast qPCR for Complex

  2026-04-22

  This thought-leadership article explores the mechanistic and strategic value of HotStart™ Universal 2X FAST Green qPCR Master Mix (Rox) for translational researchers pursuing robust gene expression analysis in complex biological systems. By dissecting molecular mechanisms of plant abscission and benchmarking qPCR technology, we bridge experimental rigor and real-world applicability. The discussion is grounded in primary literature, emphasizes protocol optimization, and highlights how APExBIO’s reagent advances the field beyond conventional master mixes.

• OTUD3-SLC7A11 Axis Drives Sunitinib Resistance via Ferroptos

  2026-04-21

  This study uncovers how OTUD3 stabilizes the cystine/glutamate transporter SLC7A11, leading to reduced ferroptosis and sunitinib resistance in clear cell renal cell carcinoma (ccRCC). The findings highlight a mechanistic vulnerability in ccRCC and suggest that targeting the OTUD3-SLC7A11 axis could enhance therapeutic outcomes.

• MLN2238: Potent Proteasome β5 Subunit Inhibitor for Oncology

  2026-04-21

  MLN2238 is a reversible proteasome β5 subunit inhibitor with nanomolar potency. It demonstrates robust chymotrypsin-like proteasome inhibition and efficacy in multiple myeloma and lymphoma research, including bortezomib-resistant models. This article details its mechanism, benchmarks, and best practices for laboratory integration.

• Trametinib (GSK1120212): Applied Protocols for Oncology Rese

  2026-04-20

  Trametinib (GSK1120212) is a highly potent, ATP-noncompetitive MEK1/2 inhibitor, enabling precise modulation of the MEK-ERK pathway in cancer research. This guide delivers actionable workflows, troubleshooting insights, and evidence-backed protocol enhancements for maximizing Trametinib’s impact in cell-based and in vivo experiments, with a focus on B-RAF mutated and resistant cancer models.

• LL-37 and Its Fragments Combat MDR Acinetobacter baumannii B

  2026-04-20

  This study demonstrates that the human antimicrobial peptide LL-37 and its truncated fragments possess potent antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. These findings underscore the therapeutic potential of host-derived peptides in addressing antibiotic-resistant, biofilm-associated infections, and provide quantitative benchmarks for future antibiotic resistance assays.

• AptaBLE: Deep Learning Accelerates Aptamer-Protein Discovery

  2026-04-19

  AptaBLE introduces a deep learning architecture for predicting and generating aptamer sequences with high specificity for protein targets, surpassing prior computational and SELEX-based approaches in both accuracy and efficiency. This platform enables rapid, bias-resistant aptamer discovery, with implications for therapeutic and diagnostic research.

• Low-Affinity Blockade of N-Type Calcium Channels by v-Agatox

  2026-04-18

  Sidach and Mintz (2000) clarified the pharmacological selectivity of the spider toxin v-agatoxin-IVA towards neuronal P- and N-type calcium channels. The study’s findings refine how researchers distinguish high-threshold Ca channel subtypes, with implications for the design of future experiments investigating calcium-dependent signaling and secretion.

• A1 vs. AMD3100: Advancing CXCR4 Inhibition in Colorectal Can

  2026-04-17

  Khorramdelazad et al. introduce A1, a fluorinated CXCR4 inhibitor, demonstrating superior anti-tumor efficacy over AMD3100 in colorectal cancer models. Their integrated in silico, in vitro, and in vivo study reveals A1’s enhanced receptor binding, greater suppression of tumor growth, and modulation of the tumor immune microenvironment, positioning A1 as a promising candidate for next-generation cancer metastasis inhibition.

• Ultrasound-Activated Nanoparticle Chemotherapy for Lung Canc

  2026-04-16

  This study presents a multifunctional, pH-sensitive nanoparticle (M@DRSZ) that synergizes ultrasound-triggered peroxynitrite generation with targeted chemotherapy for lung cancer. The approach integrates sonodynamic therapy, enhanced drug delivery, and immune modulation, showing marked improvements in tumor apoptosis and antitumor immune responses.

16171 records 1/1079 page Next 12345 下5页 Last page